CATIE Cost-Effectiveness Study Favors Perphenazine Over Atypicals

The first-generation antipsychotic perphenazine (Schering-Plough's Trilafon and generics) is less costly and just as effective in treating schizophrenia as second-generation antipsychotics, according to an economic analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) program